A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
Martijn J H G SimonsPeter M MachielsenJelle A SpoorendonkTim IgnacioPieter B DrostTim JacobsFelix E deJonghPublished in: Journal of medical economics (2024)
Implementing Oncotype DX testing in this population can prevent unnecessary overtreatment, reducing clinical and economic burden on the patient and Dutch healthcare system.